UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8 - K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported) June 9, 2016

 

PROTEON THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

     
Delaware 001-36323 20-4580525
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

 

200 West Street

Waltham, MA 02451

(Address of principal executive offices) (Zip Code)

 

(781) 890-0102

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

  o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

Introductory Comment

 

  Throughout this Current Report on Form 8-K, the terms “we,” “us,” “our” and “Company” refer to Proteon Therapeutics, Inc.

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

  (a)  The Company’s annual meeting of stockholders was held on June 9, 2016. 
   
  (b)  The stockholders elected all of the Company’s nominees for directors and ratified the appointment of Ernst and Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016.  The tabulation of votes for each proposal is as follows:
   
  Proposal 1 – Election of Directors

 

    For Withheld Broker Non-Votes
  Hubert Birner, Ph.D. 12,433,823 334,395 832,083
  Stuart A. Kingsley 12,758,146 10,072 832,083

 

  Proposal 2 – Ratification of Independent Registered Public Accounting Firm

 

    For Against Abstentions
    13,585,449 14,852 0

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 13, 2016

 

   
       
  Proteon Therapeutics, Inc.  
       
  By: /s/ Timothy P. Noyes  
  Name: Timothy P. Noyes  
  Title: President & Chief Executive Officer